Location: Cambridge MA
Cambridge, MA-based H3 Biomedicine (H3B) is a leading company in cancer genomics driven drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million in initial funding from Eisai, plus a continued ongoing commitment to fund H3B’s robust discovery pipeline and clinical programs. Now with three clinical stage anti-cancer molecules in active development, H3B is able to uniquely leverage distinct insights from cancer genomics and real-life patient data to advance its projects to clinical proof of concept and beyond. H3B embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company, to create a prolific drug discovery engine and partnership platform.
The Head of Clinical Operations is responsible for the planning and integration of all Clinical Operations and related Compliance and Quality activities. He/she defines Clinical Operations performance standards and ensures Clinical Operations team effectiveness. He/she ensures that both internal and external Clinical Operations resources are allocated optimally. He/she will work in partnership with Development Leadership and other functions within H3 Biomedicine and Eisai and the various CROs and vendors to ensure top quality execution within agreed timelines and budget. Additionally, this role will be responsible for optimizing cost efficiencies and continually seeking to improve clinical trial processes and resource utilization in close collaboration with all clinical partners and support functions. He/she is a member of the Clinical Development Leadership Team and reports to the H3 Head of Development/CMO.
Principal Duties and Responsibilities
About H3 Biomedicine Inc.
H3 Biomedicine Inc. is a privately-held, uniquely-structured oncology discovery enterprise whose sole mission is to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue the most promising current opportunity in cancer therapeutics: patient-based, genomics-driven, small molecule drugs.